Bioidentical hormones: What is all the hype about

Climacteric

Volumn 13, Issue 1, 2010, Pages 1-3

  Panay, Nick ^a   Fenton, Anna ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOIDENTICAL HORMONE; ESTROGEN; HORMONE; PROGESTERONE; TESTOSTERONE; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; EDITORIAL; ENDOCRINE DISEASE; HORMONE SUBSTITUTION; HUMAN; PHARMACY; PRIORITY JOURNAL;

BREAST; CARDIOVASCULAR SYSTEM; DRUG COMPOUNDING; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PROGESTERONE; TECHNOLOGY, PHARMACEUTICAL; WOMEN'S HEALTH;

EID: 75149186597     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903550250     Document Type: Editorial

References (7)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
2. Panay N, Ylikorkala O, Archer DF, Rakov V, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120-131
3. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151-157
4. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275: 370-375
5. Harman SM, Brinton EA, Cedars M, et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12
6. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003;46(Suppl 1):S55-8
7. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology-and hormone receptordefined invasive breast cancer. J Clin Oncol 2008;26:1260-1268